Allegion US will demonstrate interoperable electronic access control technologies and software at ISC East 2026, taking place ...

And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...

I want to leave my home's lighting and air conditioning to AI. But I don't really like the idea of having everything ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC / cancer, cancer care, Cancer research, cancer ...

The Blue Yeti made it easy to get started with a USB microphone, but there's plenty of competition now for anyone who wants ...

A summary of four recent studies evaluating locoregional therapies for hepatocellular carcinoma and percutaneous ablation for ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

Key Insights From ESMO 2026 / A. Benmaziane, B. Chibaudel, B. Goldenberg, biopsy, Breast Cancer, C. Coutzac, C. Cremolini, C.

In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

None ...